A Phase 1 interventional study of empasiprubart SC AI and empasiprubart IV in Healthy Volunteers, sponsored by argenx. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-28.
Sponsored by argenx · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study aims to see how the body reacts to empasiprubart, administered using an autoinjector (AI). The study will also look at other effects of empasiprubart, how it works in the body, and if it is safe.
The study consists of 2 parts: parts A and B. In part A, eligible participants will be randomized to receive empasiprubart SC AI via abdomen, empasiprubart SC AI via thigh, or empasiprubart IV (intravenously). In part B, eligible participants will be randomized to receive empasiprubart SC AI via abdomen or empasiprubart IV.
Participants from part A will be in the study for approximately up to 37 weeks . Participants from part B will be in the study for up to approximately 43 weeks.
argenx is the lead sponsor of 87 studies on the registry; 28 are open to participants now.
Of its 22 completed or terminated interventional studies of FDA-regulated products, 16 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants randomized to receive empasiprubart SC AI via abdomen.
Biological: empasiprubart SC AI
Participants randomized to receive empasiprubart SC AI via thigh.
Biological: empasiprubart SC AI
Participants randomized to receive empasiprubart IV.
Biological: empasiprubart IV
Participants randomized to receive empasiprubart IV and empasiprubart SC AI.
Biological: empasiprubart SC AI · Biological: empasiprubart IV
Participants randomized to receive empasiprubart IV.
Biological: empasiprubart IV
Subcutaneous injection of empasiprubart via Autoinjector (AI).
Intravenous infusion of empasiprubart
aBA via abdomen as assessed by AUC0-inf SC versus AUC0-inf IV
aBA = absolute bioavailability; AUC0-inf=area under the concentration-time curve from time 0 to infinity; PK = pharmacokinetics; SC = subcutaneous, IV = intravenous
Time frame: Up to 33 weeks
aBA via thigh as assessed by AUC0-inf SC versus AUC0-inf IV
aBA = absolute bioavailability; AUC0-inf=area under the concentration-time curve from time 0 to infinity; PK = pharmacokinetics; SC = subcutaneous, IV = intravenous
Time frame: Up to 33 weeks
Ctrough at week 8
Ctrough = trough concentration
Time frame: Up to 8 weeks
empasiprubart Cmax
Cmax = maximum observed concentration
Time frame: Up to 33 weeks
AUCw4-8 over time
AUCw4-8 = area under the concentration-time curve from week 4 to week 8
Time frame: Up to 39 weeks
Cavg over time
Cavg = average concentration
Time frame: Up to 39 weeks
Ctrough over time
Ctrough = trough concentration
Time frame: Up to 39 weeks
Percentage change from baseline in free C2 and total C2 over time
C2 = complement component 2
Time frame: Up to 33 weeks (Part A) + up to 39 weeks (Part B)
Incidence of ADA against empasiprubart in serum
ADA = antidrug antibody(ies)
Time frame: Up to 33 weeks (Part A) + up to 39 weeks (Part B)
Incidence of AEs, SAEs, and AEs leading to empasiprubart discontinuation
AE=adverse event; SAE=serious adverse event
Time frame: Up to 33 weeks (Part A) + up to 39 weeks (Part B)
Started Mar 2026 (actual). Primary completion is estimated for Mar 2027, 12 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Empasiprubart